10 
Dr. Gorovitz said he was uncomfortable with the language stating the working 
qrouo judges it appropriate "to approve these protocols if they satisfactorily 
address the questions raised" in the document. He thought including such lan- 
guage might make it impossible to disapprove of protocols if the investigator 
simply provides adequate answers to these questions. He felt the working group 
should not use language which would commit it to a specific position. Mr. Capron 
agreed; he suggested the working group modify Dr. Grobstein's proposed language. 
Dr. Grobstein said the points to consider document could indicate the working 
group will consider a nurrber of issues in reviewing protocols but not indicate 
the terms of review. Certain issues could, however, be highlighted in the 
document. 
Dr. Gottesman said the working group might indicate there are no wrong or 
right answers for seme of these questions, but these issues wall be considered 
during protocol review. 
Dr. Tern in called the attention of the working group to the third question in 
Dr. Grobstein's proposed language which reads: 
"Does the proposed somatic cell gene therapy contribute toward: 
(a) intentional germ line gene therapy; (b) the enhancement of, rather 
than the correction of defects in, human capabilities through genetic 
means; or (c) governmental or other programs with eugenic objectives?" 
Dr. Temin said the answer to ail these questions is yes; the knowledge gained 
through somatic cell huiran gene therapy will contribute to the information 
base necessary for intentional germ line therapy. Since the answers are yes, 
he questioned the rationale for including these issues in the form of questions 
in the points to consider document. 
Mr. Capron said the working group might indicate its attitude towards such 
applications. A serious study on social control of these processes might be 
necessary; everything that can be done need not always be done. 
Mr. Capron pointed out that research in other scientific areas will also provide 
information which will increase the capability of impl orienting human germ line gene 
therapy. He felt the working group might also address this issue. 
Dr. Grobstein thought research with mice and cattle is moving society much more 
rapidly towards possible human germ line gene therapy than would human somatic 
cell gene therapy. Dr. Temin said application of somatic cell gene therapy 
would, however, permit society to begin thinking in terms of genetically modi- 
fying humans. 
Dr. Walters felt the working group's mandate is to ra/iew somatic cell human 
gene therapy on a case-by-case basis. Discussing issues such as the impact of 
research on the capability of implementing human germ line gene therapy may ex- 
ceed the working group mandate. 
[ 95 ] 
